SCHEMBL2833938

SCHEMBL2833938

COc1cc(C)c(S(=O)(=O)N(CCCOc2nccc(N3CCC4(CCN(c5ccncc5)CC4)CC3)n2)C2CC2)c(C)c1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 6/20 0.39
CYP3A4 P08684 4/20 0.39
CYP1A2 P05177 2/20 0.39
TSHR P16473 5/20 0.36
CYP2C9 P11712 5/20 0.36
HIF1A Q16665 2/20 0.36
CYP2C19 P33261 2/20 0.36
BDKRB1 P46663 5/20 0.34
ITGB3 P05106 4/20 0.34
ITGA2B P08514 4/20 0.34
F10 P00742 1/20 0.34
FFAR4 Q5NUL3 2/20 0.34
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HPGD P15428 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12342559 0.96 CYP2D6 (0.39) CYP2D6CYP3A4CYP1A2TSHRCYP2C9
Hydrochloric Acid SCHEMBL2836680 0.95 CYP2D6 (0.39) CYP2D6CYP3A4CYP1A2TSHRCYP2C9
SCHEMBL2836485 0.93 CYP3A4 (0.37) CYP2D6CYP3A4CYP1A2TSHRCYP2C9
SCHEMBL2832213 0.91 CYP3A4 (0.38) CYP2D6CYP3A4CYP1A2TSHRCYP2C9
SCHEMBL2832089 0.88 BDKRB1 (0.33) CYP2D6CYP3A4CYP1A2BDKRB1ITGB3
SCHEMBL2834669 0.87 CYP2D6 (0.39) CYP2D6CYP3A4CYP1A2TSHRCYP2C9
SCHEMBL2836460 0.87 CYP2D6 (0.41) CYP2D6CYP3A4CYP1A2TSHRCYP2C9
SCHEMBL2364196 0.84 BDKRB1 (0.40) BDKRB1FFAR4
SCHEMBL2833911 0.84 CYP2D6 (0.39) CYP2D6CYP3A4CYP1A2TSHRCYP2C9
Hydrochloric Acid SCHEMBL2831731 0.84 BDKRB1 (0.40) BDKRB1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US claimed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US claimed
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP disclosed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS CYP2D6 1157/4885CYP3A4 1682/4885CYP1A2 1085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.